cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Hilwan Yuda Teruna
Contact Email
hilwan@iai.id
Phone
+6221-56962581
Journal Mail Official
info@jfi-online.org
Editorial Address
Pengurus Pusat Ikatan Apoteker Indonesia Jalan Wijayakusuma No. 17 Tomang, Jakarta Barat Jakarta 11430
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Jurnal Farmasi Indonesia
Published by Ikatan Apoteker Indonesia
ISSN : 14121107     EISSN : 2355696X     DOI : https://doi.org/10.35617/jfionline
Core Subject : Health,
Medicine & Pharmacology
Jurnal Farmasi Indonesia adalah jurnal nasional (peer-reviewed) yang diterbitkan oleh Ikatan Apoteker Indonesia dua kali dalam setahun sebagai sarana diseminasi ilmu pengetahuan di bidang farmasi, yaitu: farmasi klinis, farmasi masyarakat/komunitas, kimia farmasi, biologi farmasi/famakognosi, farmakologi, pengembangan obat/kimia medisinal, formulasi dan bidang terkait. Artikel yang dipublikasi berupa hasil penelitian dan mini-review. JFIOnline telah mulai diterbitkan sejak tahun 2009 dalam edisi cetak. Pada tahun 2014 mulai dibuat edisi online. Akses artikel pada jurnal tidak berbayar, tetapi dikenakan biaya proses publikasi untuk penulis (open access journal). Mulai bulan Juli 2019 jurnal ini dapat diakses di alamat yang baru yaitu www.jfi-online.org dari alamat sebelumnya www.jfionline.org.
Arjuna Subject : Profesi Kesehatan - Farmasi
Articles 172 Documents
 14   15   16   17   18 
ANALISIS PERBANDINGAN METODE TAM DAN METODE UTAUT 2 DALAM MENGUKUR KESUKSESAN PENERAPAN e-Puskesmas DI PUSKESMAS KABUPATEN GROBOGAN Indrasari, Ferika; Lestari, Windy Nur; Sulaeman, Agus
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol 17 No 2 (2025): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v17i2.863

Abstract

The application of information technology in the health sector, especially the e-Puskesmas system, is intended to improve the quality of services at the Grobogan Regency Community Health Center. The main objective of the study was to analyze the comparison between two models: the Technology Acceptance Model (TAM) and the Unified Theory of Acceptance and Use of Technology 2 (UTAUT 2). The study was conducted at the Grobogan Regency Community Health Center from January to March 2025. The population in this study was pharmaceutical personnel at the Grobogan Regency Community Health Center, and the sample in the study consisted of 90 people. The method in this study was comparative quantitative, with data quality testing using validity tests, reliability tests, and one-way ANOVA tests. The results of the one-way ANOVA test showed no significant difference between the TAM method and the UTAUT 2 method, with a sig value of 0.773 > α (0.05), which means there was no significant difference between the TAM method and the UTAUT 2 method in measuring the success of the implementation of the Puskesmas at the Grobogan Regency Community Health Center. This study canit can be concluded that in this study there is no significant difference between the TAM Method and the UTAUT 2 Method in measuring the success of the implementatione-Puskesmasat the Community Health Centers in Grobogan Regency.
Investigasi Potensi Antiviral Ekstrak Biji Kopi Robusta Temanggung Dalam Menghambat Virus Dengue (DENV) Sawal, Rizky Ardian Hartanto; Solichah, Ayu Ina; Puspitasari, Ismi; Daiman, Felina
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol 17 No 2 (2025): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v17i2.883

Abstract

Dengue Hemorrhagic Fever (DHF) is a significant health issue in tropical and subtropical regions. The discovery of new antiviral agents is crucial due to the lack of effective treatment or vaccines. This study aims to explore the potential of Temanggung robusta coffee bean extract as an anti-DENV agent. The coffee beans were extracted through maceration using 96% ethanol, followed by phytochemical screening to identify active compounds such as alkaloids, flavonoids, saponins, and tannins. Anti-DENV activity and Vero cell cytotoxicity tests were conducted to evaluate the extract's effectiveness and safety. Results indicated that robusta coffee extract exhibited anti-DENV activity with an EC50 of 88.51 µg/ml and a Selectivity Index (SI) of 9.82. The antiviral activity is attributed to bioactive compounds like alkaloids, flavonoids, saponins, and tannins that inhibit DENV replication. Although the extract demonstrated cytotoxicity at high concentrations with CC50 of 869.7 µg/ml, it still holds potential as a therapeutic anti-DENV agent with relatively low toxicity risks. This research opens opportunities for developing robusta coffee-based therapies for DENV infection control in the future.

Page 18 of 18 | Total Record : 172

 14   15   16   17   18 

Filter by Year

2019 2026


Reset
Filter By Issues
All Issue Vol 18 No 1 (2026): Jurnal Farmasi Indonesia Vol 17 No 2 (2025): Jurnal Farmasi Indonesia Vol 17 No 1 (2025): Jurnal Farmasi Indonesia Vol 16 No 2 (2024): Jurnal Farmasi Indonesia Vol 16 No 1 (2024): Jurnal Farmasi Indonesia Vol. 16 No. 1 (2024): Jurnal Farmasi Indonesia Vol 15 No 2 (2023): Jurnal Farmasi Indonesia Vol 15 No 1 (2023): Jurnal Farmasi Indonesia Vol 14 No 2 (2022): Jurnal Farmasi Indonesia Vol 14 No 1 (2022): Jurnal Farmasi Indonesia Vol 13 No 2 (2021): Jurnal Farmasi Indonesia Vol 13 No 1 (2021): Jurnal Farmasi Indonesia Vol. 12 No. 2 (2020): Jurnal Farmasi Indonesia Vol. 12 No. 1 (2020): Jurnal Farmasi Indonesia Vol. 11 No. 2 (2019): Jurnal Farmasi Indonesia Vol 11 No 2 (2019): Jurnal Farmasi Indonesia More Issue